Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive heart attack registry aims to save lives in korea

NCT ID NCT07409441

Knowledge-focused Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study will enroll 20,000 Korean adults who have had a heart attack (acute myocardial infarction). Researchers will collect detailed data from hospitals nationwide to understand what factors affect long-term outcomes. The goal is to create better risk prediction tools and treatment guidelines tailored to the Korean population, ultimately improving survival and quality of life after a heart attack.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could lead to better risk prediction models and treatment guidelines specifically for Korean heart attack patients, potentially improving survival and care quality.
What could go wrong
This is an observational study, not a treatment trial, so it cannot directly test new therapies. Results may take years to influence clinical practice, and data quality depends on consistent reporting from many hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study participants are patients aged 19 years or older diagnosed with acute myocardial infarction who are enrolled at participating hospitals in Korea as part of the KAMIR-7 registry and followed for up to 3 years.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 19 years * Patients diagnosed with acute myocardial infarction (AMI) (either ST-segment elevation myocardial infarction \[STEMI\] or non-ST-segment elevation myocardial infarction \[NSTEMI\]), meeting both of the following: * Elevated cardiac troponin above the 99th percentile upper reference limit * Evidence of myocardial ischemia, as indicated by symptoms, electrocardiographic (ECG) changes, and/or imaging evidence Exclusion Criteria: \- Patients who do not provide informed consent to participate in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction, acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction myocardial infarction Non-ST Elevated Myocardial Infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction, acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Samsung Medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.